PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Translocation, Genetic”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources
PubMed2006

On the location of the gene(s) harbouring the advantageous variant that maintains the X/4 fusion of Drosophila americana.

Weak selection is maintaining the Drosophila americana X/4 fusion chromosomal frequency cline. The gene(s) harbouring the advantageous variant(s) that is responsible for the establishment and maintenance of this chromosomal frequency gradient must be located in a region of the X and/or 4th chromosome that is genetically isolated between the X/4 fusion and non-fusion forms. The limits of these regions must thus be determined before an attempt is made to identify these genes. For this purpose, the correspondence between the D. virilis X and 4th chromosome genome scaffolds sequence and the D. americana gene order was established. Polymorphism levels and patterns at seven genes located at the base of the D. americana X chromosome, as well as three genes located at the base of the 4th chromosome, were analysed. The data suggest that the D. americana X/4 fusion is no more than 29,000 years old. At the base of the X chromosome, there is suppression of recombination within X/4 fusion and non-fusion chromosomes, and little recombination between the two chromosomal forms. Apparent fixed silent and replacement differences are found in three of seven genes analysed located at the base of the X chromosome. There is no evidence for suppression of recombination between fusion and non-fusion chromosomes at the base of the 4th chromosome. The advantageous variant responsible for the establishment in frequency and maintenance of the X/4 fusion is thus inferred to be in the D. americana X centromere-inversion Xc basal breakpoint region.

Animals↗
PubMed2001

snoRNA nuclear import and potential for cotranscriptional function in pre-rRNA processing.

Several snoRNAs are essential for the sequence of cleavage events required to produce the mature forms of 18S, 5.8S, and 28S rRNA from the large precursor molecule. In the absence of U22, mature 18S rRNA fails to accumulate; U8 snoRNA is essential for accumulation of both 5.8S and 28S rRNA. The mechanisms by which snoRNAs facilitate these cleavage events is not known and might include direct cleavage or assisting the rate or efficiency of ribosome assembly. To learn more about the mechanisms of snoRNA-mediated pre-rRNA processing, an examination of the kinetics of pre-rRNA processing in Xenopus oocytes was undertaken. Correct pre-rRNA processing can be restored in snoRNA-depleted oocytes following cytoplasmic injection of the corresponding in vitro-synthesized snoRNA. Analysis of the kinetics of pre-rRNA processing in these snoRNA-rescue experiments demonstrated that the rate of accumulation of mature rRNAs was slower than that seen in untreated oocytes. The snoRNAs were imported into the nucleus at a rate and overall efficiency less than that of U1 snRNA, used as a control for import. However, sufficient levels of snoRNA were present in the nucleus to yield a functional phenotype (rescue of rRNA processing) several hours before the snoRNAs were directly detectable in the nucleus via autoradiography. This indicated that very low amounts of the snoRNA in the nucleus were sufficient for rescue. Finally, transcriptional inhibitors were used to separate transcription and processing. Failure to rescue snoRNA-mediated processing of pre-accumulated precursors is consistent with a scenario in which U8 and U22 must be present during transcription of pre-rRNA.

Active Transport, Cell Nucleus↗
PubMed1980

The joining of V and J gene segments creates antibody diversity.

The variable regions of mouse kappa (kappa) chains are coded for by multiple variable (V) gene segments and multiple joining (J) gene segments. The V kappa gene segments code for residues 1 to 95; the J kappa gene segments code for residues 96 to 108 (refs 1-3). This gene organisation is similar to that encoding the V lambda regions. Diversity in V kappa regions arises from several sources: (1) there are multiple germ-line V kappa gene segments and J kappa gene segments; (2) combinatorial joining of V kappa gene segments with different germline J kappa gene segments; and possibly, (3) somatic point mutation, as postulated for V lambda gene segments. Also, from a comparison of the number of germ-line J kappa gene segments and amino acid sequences, it has been suggested that J kappa region sequences may be determined by the way V kappa and J kappa gene segments are joined. This report supports this model by directly associating various J kappa sequences with given J kappa gene segments.

Animals↗
PubMed1981

Recombination suppression of mouse t-haplotypes due to chromatin mismatching.

We show here that recombination occurs at the normal rate in compound female mice containing two different complementing lethal haplotypes (th17/tw12) where there is a long stretch of homologous t-mutant chromatin. Thus the recombination suppression of a complete t-haplotype cannot be due to an intrinsic factor(s) which suppresses along the length of its own chromosome but is due to 'mismatching' of wild-type and mutant chromatin. Naturally occurring t-haplotypes of mouse chromosome 17 have several interesting genetic properties. First, they are always transmitted from males in much higher proportions than mendelian expectation; presumably this accounts for the maintenance of lethal and semilethal t-haplotypes at polymorphic levels in populations of wild mice. t-Haplotypes also show recombination suppression. The conventional map distance between genetic markers T and tf is 7-12 cM, whereas in (t/+) heterozygotes for naturally occurring t-haplotypes, recombination is suppressed and T and tf seem to be separated by only 0.1-0.5 cM (ref. 1). The region of recombination suppression extends to and includes the major histocompatibility complex (H-2). Thus t and H-2 effectively travel as a single unit-- a 'super gene'. Although recombination suppression is known to be accompanied by failure of chiasmata formation, the mechanism underlying the suppression has remained an enigma. Lyon suggested a disorder of t-heterochromatin and more recently a change in 'intercalary' middle repetitive DNA. She proposed that either t-chromatin is intrinsically incapable of participating in crossing-over, or chiasma formation is prevented because of mismatching and mispairing of normal and abnormal chromatin. We have measured recombinant between two chromosomes which carried extensive overlapping segments of t-chromatin. We report here that in this configuration, recombination occurs at a normal rate, and thus we conclude that cross-over suppression is due to mismatching.

Animals↗
PubMed1993

Recombinations of chromosomal bands 6p21 and 14q24 characterise pulmonary hamartomas.

Cytogenetic analysis of short-term cultures from seven pulmonary hamartomas revealed an abnormal karyotype in six of them. The most characteristic aberration was an exchange of material between 6p21 and 14q24, found in three tumours. Abnormalities of either 6p or 14q were seen in another two hamartomas. Other regions that were rearranged more than once were 12q (three times) and 17p (twice), sometimes in exchange with 6p or 14q and giving rise to complex derivative chromosomes. Only one tumour had aberrations that did not involve 6p, 12q, 14q, or 17p. These results-together with the data on three previously reported pulmonary hamartomas, two of which also had t(6;14)-show that recombinations between 6p21 and 14q24 are common, and hence probably pathogenetically important. The data support the view that these tumours are genuine neoplasms rather than developmental anomalies. The coexistence of a common 14q24 breakpoint in uterine leiomyomas and pulmonary hamartomas indicates that a gene important in the genesis of both tumours exists in this band.

Adult↗
PubMed1997

Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family.

Holt-Oram syndrome is a developmental disorder affecting the heart and upper limb, the gene for which was mapped to chromosome 12 two years ago. We have now identified a gene for this disorder (HOS1). The gene (TBX5) is a member of the Brachyury (T) family corresponding to the mouse Tbx5 gene. We have identified six mutations, three in HOS families and three in sporadic HOS cases. Each of the mutations introduces a premature stop codon in the TBX5 gene product. Tissue in situ hybridization studies on human embryos from days 26 to 52 of gestation reveal expression of TBX5 in heart and limb, consistent with a role in human embryonic development.

Abnormalities, Multiple↗
PubMed2000

Differentiation therapy in acute myelogenous leukemia (non-APL).

Successful treatment of acute promyelocytic leukemia (APL) has identified several novel approaches to induce leukemic cell differentiation and selective apoptosis by overcoming the site-specific transcriptional repression by dominant fusion leukemogenic proteins characteristic of APL and other forms of acute myelogenous leukemia (AML). These therapeutic approaches include the use of site-specific ligands, receptors and cytokines, disruption of dominant fusion leukemogenic proteins, chromatin remodeling and combining the above with cytotoxic chemotherapy. With the exception of cytotoxic chemotherapy, the above therapeutic strategies do not significantly affect normal hematopoiesis and their combinations have been shown to be synergistic in inducing myeloid differentiation and apoptosis in several AML cell lines and in patients with APL. These approaches are, in general, non-cross resistant and should be well tolerated particularly in elderly patients with AML. Clinical studies which include biologic end points for differentiation induction, histone acetylation and selective apoptosis are presently in development to evaluate these strategies in the treatment of AML.

Acute Disease↗